Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 75/100

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Monday, August 25, 2025 2 min read
Key Takeaway: BridgeBio Pharma has announced that it will present additional data from the ATTRibute-CM study at the upcoming ESC Congress 2025 in Madrid. The presentations will include findings on the effectiveness of Attruby in reducing cardiovascular mortality in ATTR-CM patients, with specific details shared in rapid-fire presentations and ePosters. Despite the positive data, some adverse reactions have been noted among patients treated with Attruby, although these were generally mild and manageable.

Market Sentiment Analysis

POSITIVE FACTORS

  • BridgeBio is presenting new data from the ATTRibute-CM study, indicating progress in their research.
  • The drug Attruby shows promise in reducing cardiovascular mortality in patients with ATTR-CM.
  • The upcoming presentations at ESC Congress 2025 could enhance visibility and interest in the drug.

CONCERNS & RISKS

  • Some patients experienced adverse reactions like diarrhea and abdominal pain while on Attruby.
  • The reported adverse reactions, though mostly mild, may concern potential users and healthcare providers.

Full Press Release Details

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.
Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study
Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, USA
Date: Saturday, August 30 at 1:15 pm CEST/7:15 am ET
Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D. of UChicago Medicine, USA
Date: Sunday, August 31 at 4:15 pm CEST/10:15 am ET
Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UK
Date: Saturday, August 29 at 3:15 pm CEST/9:15 am ET
About Attruby™ (acoramidis)
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance

Frequently Asked Questions

What is BridgeBio Pharma focused on?

BridgeBio Pharma specializes in developing treatments for genetic diseases.

When is the ESC Congress 2025 taking place?

The ESC Congress 2025 is scheduled for August 29 to September 1, 2025.

What is Attruby indicated for?

Attruby is used to treat cardiomyopathy in adults with transthyretin-mediated amyloidosis.

What adverse reactions are associated with Attruby?

Common side effects include diarrhea and upper abdominal pain, mostly mild.

Who will present at the ESC Congress?

Presenters include Dr. Kevin Alexander and Dr. Nitasha Sarswat from notable institutions.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio ATTRibute-CM Acoramidis ESC Congress 2025 cardiovascular mortality
Last updated: Aug 25, 2025